RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets

Quest Diagnostics (DGX) will offer Roche's FDA-cleared pTau217 blood test for Alzheimer's assessment, expanding its AD-Detect® portfolio. The test will be available Q4 2026. Quest also launches a new multi-biomarker AD-Detect test with a 10% indeterminate rate, aiming to provide more actionable insights for patients.

Apple plans to launch a foldable iPhone Ultra priced above $2,000 in early September, according to reports. The device will feature a pocket-friendly design, advanced hinge, and iPad-like app layouts, but lack a telephoto camera and Face ID. Foldable phones currently hold a 1.6% market share, with China driving significant sales. The launch marks Apple's first new product form factor since 2023.

Nvidia plans to use its $6bn deal with AI startup Poolside to build open-weight AI models, competing with China's DeepSeek and Moonshot. The deal includes $1bn in equity at a $12bn valuation. Nvidia's CEO Jensen Huang emphasized the importance of open-weights for US AI leadership. Poolside's 109 employees will join Nvidia to work on the Nemotron project, aiming to develop open-weight models.

Labcorp (NYSE: LH) announced it will offer the Elecsys® pTau-217 blood test, the first FDA-cleared single-biomarker test to detect Alzheimer's disease pathology. Developed by Roche Diagnostics, the test measures phosphorylated Tau 217, an indicator of amyloid pathology, in individuals 55 and older with cognitive decline symptoms. The test will be available nationwide in primary and specialty care settings, providing a standardized approach to patient assessment. Labcorp plans to make the test av

Parsons (NYSE: PSN) secured a $514 million, two-year contract option from the Missile Defense Agency (MDA) to continue providing engineering, technical, and oversight support for the U.S. integrated Missile Defense System. The contract covers advanced systems engineering and solutions to protect against ballistic and hypersonic threats across multiple domains.

Eli Lilly (NYSE:LLY) launched its weight loss and type 2 diabetes pill, Foundayo, in the UK. The oral treatment, priced between £100-£120 per month, is available via private prescription. Novo Nordisk's (CSE:NOVO-B) Wegovy is already on the market. Foundayo is under review for NHS coverage and in the EU.